Summary
Biogen Inc. (BIIB) announced on August 14, 2024, through an 8-K filing, the entry into a new $1.5 billion, five-year unsecured, revolving credit facility with Bank of America, N.A. This new facility replaces the Company's previous credit agreement. As of the closing date, no funds had been drawn under this new facility, indicating Biogen maintains a strong liquidity position. The new credit agreement provides Biogen with significant financial flexibility for general corporate purposes. The interest rates are variable, tied to benchmark rates like SOFR, EURIBOR, etc., plus an applicable margin that depends on the Company's debt ratings. The facility includes sub-limits for letters of credit and swing line loans. Importantly, the agreement includes a financial covenant requiring Biogen to maintain a consolidated leverage ratio of no more than 3.75 to 1.0, with a temporary increase allowed to 4.25 to 1.0 in case of material acquisitions.
Key Highlights
- 1Biogen entered into a new $1.5 billion, five-year unsecured, revolving credit facility.
- 2The new facility is effective as of August 12, 2024, with Bank of America, N.A. as the Administrative Agent.
- 3No borrowings were outstanding under the new credit facility as of the closing date, indicating ample liquidity.
- 4The facility is available for general corporate purposes, offering financial flexibility.
- 5Interest rates are variable, linked to benchmark rates (Term SOFR, EURIBOR, etc.) plus a margin based on Biogen's debt ratings.
- 6A key financial covenant requires maintaining a maximum consolidated leverage ratio of 3.75 to 1.0 (extendable to 4.25 to 1.0 for acquisitions).
- 7The existing credit agreement was terminated simultaneously with the entry into the new agreement.